Single and Dual Chamber Leadless Pacemaker Solutions, only from Abbott
.png)
MAT-2403640 v1.0 | Item approved for U.S. use only. ©2024 Abbott. All Rights Reserved.
For the first time ever, see how Single Chamber Atrial Leadless Pacing can help patients with:
Explore Single Chamber Ventricular Leadless Pacing for patients with:
Redefine the patient experience using Dual Chamber Leadless Pacing solutions for patients living with:
Patient therapy can be tailored by implanting an atrial or ventricular device alone, or both combined for dual chamber support. The option to upgrade over time allows you to meet your patient’s needs today and adapt to common disease progression later.
Treatment option 1: Start with the atrial device.
Treat sinus node dysfunction today.
Add a ventricular device for heart block later.
i2i communication is enabled.
Activate dual chamber pacing therapy DDD(R) via i2i Communication.
Treatment option 2: Start with the ventricular device.
Treat rare intermittent heart block today.
Add an atrial device for sick sinus syndrome later.
i2i communication is enabled.
Activate dual chamber pacing therapy DDD(R) via i2i Communication.
With sensing and pacing in both the right atrium and right ventricle, you now have AAI(R), VVI(R), and DDD(R) leadless configurations to consider. You can match your patient's pacing needs today and then upgrade over time as those needs change.
To support dual chamber therapy, each implant communicates beat-to-beat with a paired, co-implanted device using i2i communication. This novel technology employs low energy, subthreshold pulses between implanted devices using the conductive nature of the body's blood pool and myocardial tissue. These high frequency pulses of data are delivered concurrently with each locally paced or sensed event, without impact on pacing or intrinsic sensing.
This allows for the replacement of the atrial or ventricular device at end of service (EOS) without leaving hardware behind.
Specialty designed retrieval catheter supported by step-by-step protocol.
Through nine years regardless of implant duration, AVEIR™ VR Leadless Pacemaker (LP) predicate device has a long-term retrieval success rate above 88%.3
Active fixation helix uses a screw-in mechanism to enable both implantation and long-term retrieval of the LP.
AVEIR VR and AVEIR AR LPs can measure P/R-waves, impedance and Current of Injury via commanded EGM, and an initial capture threshold before fixation by simply touching the electrode to the endocardial tissue.2 The LPs are engaged with a rotational motion in the endocardium, and mapping capability is designed to help reduce the number of repositioning attempts.2
References
MAT-2306873 v4.0
STAY CONNECTED